---
figid: PMC5712330__12308_2017_302_Fig5_HTML
figlink: /pmc/articles/PMC5712330/figure/Fig5/
number: F5
caption: Targeted therapy in extranodal marginal zone lymphoma. Rituximab targets
  CD20-positive B lymphoma cells, which results in anti-tumor effects related to complement-dependent
  cellular cytotoxicity and antibody-dependent cellular cytotoxicity. Upstream of
  the NF-κB pathway, different types of inhibitors may target key enzymes that are
  activated downstream of BCR signaling or affected by genetic alterations (BIRC3-MALT1
  translocation, BCL10 and MYD88 mutations [*]). These include BTK inhibitor inbrutinib
  and MALT inhibitors. BCR stimulation also activates the PI3K/AKT/mTOR pathway that
  can be targeted by PI3K inhibitors and mTOR inhibitor everolimus. Activation of
  NF-κB itself, which may also result by loss of TNFAIP3 function due to gene deletions
  or mutations [*], can be blocked by bortezomib. Lenalidomide promotes degradation
  of IKZF1 and IKZF3, thereby downregulating the expression of MYC and IRF4. Transcription
  factors FOXP1 and BCL6, which are upregulated by genetic alterations (e.g., chromosomal
  translocations, promoter mutations), as well as other epigenetic regulators that
  require HDAC activity, can be blocked by the action of HDAC inhibitors
pmcid: PMC5712330
papertitle: Novel developments in the pathogenesis and diagnosis of extranodal marginal
  zone lymphoma.
reftext: Max I. Schreuder, et al. J Hematop. 2017 Dec;10(3-4):91-107.
pmc_ranked_result_index: '139518'
pathway_score: 0.958508
filename: 12308_2017_302_Fig5_HTML.jpg
figtitle: Targeted therapy in extranodal marginal zone lymphoma
year: '2017'
organisms:
- Borreliella burgdorferi
- Campylobacter jejuni
- Helicobacter pylori
- Helicobacter heilmannii
- Chlamydia psittaci
- Chlamydia abortus
- Achromobacter xylosoxidans
- Homo sapiens
ndex: c5c8b99d-dee3-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5712330__12308_2017_302_Fig5_HTML.html
  '@type': Dataset
  description: Targeted therapy in extranodal marginal zone lymphoma. Rituximab targets
    CD20-positive B lymphoma cells, which results in anti-tumor effects related to
    complement-dependent cellular cytotoxicity and antibody-dependent cellular cytotoxicity.
    Upstream of the NF-κB pathway, different types of inhibitors may target key enzymes
    that are activated downstream of BCR signaling or affected by genetic alterations
    (BIRC3-MALT1 translocation, BCL10 and MYD88 mutations [*]). These include BTK
    inhibitor inbrutinib and MALT inhibitors. BCR stimulation also activates the PI3K/AKT/mTOR
    pathway that can be targeted by PI3K inhibitors and mTOR inhibitor everolimus.
    Activation of NF-κB itself, which may also result by loss of TNFAIP3 function
    due to gene deletions or mutations [*], can be blocked by bortezomib. Lenalidomide
    promotes degradation of IKZF1 and IKZF3, thereby downregulating the expression
    of MYC and IRF4. Transcription factors FOXP1 and BCL6, which are upregulated by
    genetic alterations (e.g., chromosomal translocations, promoter mutations), as
    well as other epigenetic regulators that require HDAC activity, can be blocked
    by the action of HDAC inhibitors
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BCL10
  - AKT3
  - AKT1
  - BCR
  - BIRC3
  - AKT2
  - BCL6
  - HDAC10
  - HDAC3
  - HDAC9
  - SIRT3
  - HDAC4
  - IKZF3
  - SIRT1
  - HDAC1
  - CARD11
  - TNFAIP3
  - TRAF6
  - SIRT2
  - HDAC11
  - HDAC2
  - MS4A1
  - IKZF1
  - SIRT4
  - PRKCB
  - HDAC6
  - SIRT6
  - IRAK4
  - FOXP1
  - IRF4
  - HDAC5
  - MYD88
  - MTOR
  - SIRT5
  - SIRT7
  - MYC
  - MALT1
  - HDAC7
  - NFKB1
  - HDAC8
  - Ibrutinib
  - Cancer
genes:
- word: BCL10*
  symbol: BCL10
  source: hgnc_symbol
  hgnc_symbol: BCL10
  entrez: '8915'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: BCR
  symbol: BCR
  source: hgnc_symbol
  hgnc_symbol: BCR
  entrez: '613'
- word: BIRC3
  symbol: BIRC3
  source: hgnc_symbol
  hgnc_symbol: BIRC3
  entrez: '330'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: BCL6
  symbol: BCL6
  source: hgnc_symbol
  hgnc_symbol: BCL6
  entrez: '604'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC10
  entrez: '83933'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC3
  entrez: '8841'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC9
  entrez: '9734'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT3
  entrez: '23410'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC4
  entrez: '9759'
- word: IKZF1/3
  symbol: IKZF3
  source: hgnc_symbol
  hgnc_symbol: IKZF3
  entrez: '22806'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT1
  entrez: '23411'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC1
  entrez: '3065'
- word: CARD11
  symbol: CARD11
  source: hgnc_symbol
  hgnc_symbol: CARD11
  entrez: '84433'
- word: TNFAIP3
  symbol: TNFAIP3
  source: hgnc_symbol
  hgnc_symbol: TNFAIP3
  entrez: '7128'
- word: TRAF6
  symbol: TRAF6
  source: hgnc_symbol
  hgnc_symbol: TRAF6
  entrez: '7189'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT2
  entrez: '22933'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC11
  entrez: '79885'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC2
  entrez: '3066'
- word: CD20
  symbol: CD20
  source: hgnc_prev_symbol
  hgnc_symbol: MS4A1
  entrez: '931'
- word: IKZF1/3
  symbol: IKZF1
  source: hgnc_symbol
  hgnc_symbol: IKZF1
  entrez: '10320'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT4
  entrez: '23409'
- word: PKCB
  symbol: PKCB
  source: hgnc_prev_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC6
  entrez: '10013'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT6
  entrez: '51548'
- word: IRAK4
  symbol: IRAK4
  source: hgnc_symbol
  hgnc_symbol: IRAK4
  entrez: '51135'
- word: FOXP1
  symbol: FOXP1
  source: hgnc_symbol
  hgnc_symbol: FOXP1
  entrez: '27086'
- word: IRF4
  symbol: IRF4
  source: hgnc_symbol
  hgnc_symbol: IRF4
  entrez: '3662'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC5
  entrez: '10014'
- word: MYD88
  symbol: MYD88
  source: hgnc_symbol
  hgnc_symbol: MYD88
  entrez: '4615'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT5
  entrez: '23408'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT7
  entrez: '51547'
- word: MYC
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: MALT1
  symbol: MALT1
  source: hgnc_symbol
  hgnc_symbol: MALT1
  entrez: '10892'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC7
  entrez: '51564'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC8
  entrez: '55869'
chemicals:
- word: Ibrutinib
  source: MESH
  identifier: C551803
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC5712330__F5
redirect_from: /figures/PMC5712330__F5
figtype: Figure
---
